Novo Nordisk to cut 400 jobs in Bloomington
The drugmaker called the move a “difficult decision” but did not provide a reason for the cuts.
Pharmaceutical
Lilly to acquire UK-based pharmaceutical company in deal worth up to $7.8B
Centessa Pharmaceuticals is developing treatments to address daytime sleepiness and other neurological conditions.
Obesity drug trials complicated by placebo patients leaving early
The companies developing new weight-loss medicines have a problem: People who don’t lose weight quickly figure out they were assigned to take a placebo and are bailing out of their clinical trials.
Lilly’s experimental diabetes shot yields record weight loss in study
The late-stage results handily beat earlier trials of the company’s diabetes blockbuster Mounjaro, which racked up sales of $23 billion in 2025.
Lilly spending $1.8B to update Indianapolis manufacturing operations
The Lilly Technology Center investment includes expanding existing capabilities and the establishment of new production lines.
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers after an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform.
Chief technology officer spent whole career at Lilly
Tim Coleman has held positions within information technology at Lilly in research and development, sales and marketing, manufacturing, and human resources.
Generic Ozempic could cost less than $3 a month, study shows
Generic Ozempic is set to emerge in major markets from India and Brazil to China and Canada this year, reshaping the sector in those countries.
GLP-1 fight plays out in statehouses, courthouses
While major drugmakers tussle for market supremacy, they are also taking on compound pharmacies that have not stopped selling obesity drugs despite the end of the shortage of such drugs.
FDA declines to review Moderna application for first mRNA-based flu vaccine
Moderna President Stephen Hoge said that the company had previously engaged with the FDA on the trial design and that the agency had indicated it would be acceptable.
Novo Nordisk vows to sue after Hims & Hers launches Wegovy knockoff pill
Shares in Indianapolis-based Eli Lilly and Co., a rival to Novo Nordisk in the weight-loss market, also fell after the announcement, dropping 7.8% Thursday.
Trump administration to launch TrumpRx website for discounted drugs
The president first teased TrumpRx in September while announcing the first of his more than 15 deals with pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., to lower drug prices.
House lawmaker raises new concerns over FDA’s ultra-fast drug review program
Under the program, drugmakers are promised expedited reviews of one to two months for new medicines that support “national interests.”
SpectronRx completes expansion of campus at Grissom Aeroplex
The Indianapolis-based radiopharmaceutical company built a 150,000-square-foot production facility and plans to add up to jobs.
Lilly, Nvidia to establish $1B AI co-innovation lab in San Francisco
The new initiative expands on the massive artificial intelligence supercomputer collaboration the companies announced last fall.
Former GLP-1 users regain lost weight after about 18 months, study says
People who stop taking GLP-1 drugs such as Ozempic, Wegovy and Zepbound for weight loss are projected to regain their shed pounds within about 1-½ years, a review of existing research has found.
Pharmaceutical company planning to employ 300 workers in Greenfield
The plant will focus on serving health care companies by developing and commercializing medical devices, drug delivery systems and combination products.
First GLP-1 weight-loss pill now available, with pledge of abundant supply
Novo Nordisk is aiming to avoid losing ground to its main rival, Eli Lilly, which is seeking regulatory approval for its own GLP-1 weight-loss pill.
Indiana attorney general sues Lilly over insulin prices
Attorney General Todd Rokita said the lawsuit, filed last Wednesday in the Lake County Superior Court, is part of his office’s intensifying efforts to lower insulin prices and improve health care affordability.
US regulators approve Wegovy pill for weight loss, giving Novo Nordisk an edge over Lilly
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.